Posted by Michael Wonder on 14 Jul 2020
Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec to include patients aged 12 years and older.
Sanofi Canada is pleased to announce a positive recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for Dupixent (dupilumab) for Quebec residents aged 12 to 17 years with moderate to severe atopic dermatitis whose disease is not adequately managed with current therapy and when specific conditions are met.
Dupixent is currently reimbursed by the Régie de l'assurance maladie Québec (RAMQ)ii and by the Non-Insured Health Benefits (NIHB) program for patients over the age of 18 with moderate to severe atopic dermatitis. Most recently, the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) issued a recommendation that DUPIXENT® (dupilumab) be reimbursed by public drug plans for Canadians aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately managed with current therapy and when specific conditions are met.
